2 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of etranacogene dezaparvovec in the NHS in England.

Etranacogene dezaparvovec is not recommended for the treatment of adults with moderately severe or severe haemophilia B (congenital factor IX deficiency) without a history of factor IX inhibitors (antibodies against factor IX).

Read NICE draft guidance consultation